Dec 5, 2017
NCT03215030: Phase 1/2: Safety, Tolerability, Efficacy, Pharmacok. Immunogenicity of TAK-573 in RRMM
Modakafusp alfa (Formerly TAK-573) NCT03215030: Phase 1/2: A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics,...
472
Dec 24, 2016
NCT01564537: Phase 3 - TOURMALINE-MM1 - Oral Ixazomib + Len/Dex Vs Placebo + Len/Dex RRMM
TOURMALINE-MM1 A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and...
326
Dec 16, 2016
NCT02765854: Phase 2: Ixazomib and Dex Vs Ixazomib, Dex and Lenalidomide, With NFKB2 Rearrangement
Multiple Myeloma Research Consortium NCT02765854: Phase 2: Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide,...
59
Dec 3, 2015
NCT02406144: Phase 3 - GEM2014MAIN - Maintenance Len, Dex VS Len, Dex. & MLN9708 After ASCT NDMM
GEM14 Phase III GEM2014MAIN: Maintenance With Ixazomib + Len/Dex vs Len/Dex After VRd + ASCT in Newly Diagnosed MM Trial Studying...
272
Dec 14, 2014
NCT02046070: Phase 2 to Evaluate the Oral Ixazomib (MLN9708) With Cyclophosphamide & Dex Myeloma
NCT02046070: Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients...
53
Dec 6, 2013
NCT01850524: Phase 3 - TOURMALINE-MM2 - Oral Ixazomib + Lenalidomide/Dex Vs Placebo + Len/Dex NDMM
TOURMALINE-MM2 IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With...
137
Dec 7, 2010
NCT01217957: Phase 1/2: A Study of Ixazomib in Combination With Lenalidomide and Low-Dex in NDMM
NCT01217957: Phase 1/2: A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With...
75
Dec 29, 2008
NCT00734877: UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myel
Toward improving the therapeutic index of standard TT3 (S-TT3), the investigators will employ a randomized Phase III trial design to...
426
Dec 3, 2008
NCT00722566: Phase 3: A Study of Subcutaneous and Intravenous VELCADE in Patients With RRMM
NCT00722566: Phase 3: A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma A Study of...
52
Dec 21, 2007
NCT00507442: Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat NDMM EVOLUTION
EVOLUTION Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients (EVOLUTION)...
108
Dec 6, 2007
NCT00507416: Phase 3: Velcade,Thalidomide, Dexamethasone Vs Velcade, Dexamethasone Vs VMP (UPFRONT)
UPFRONT NCT00507416: Phase 3: Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and...
205
Dec 14, 2006
NCT00378105: Phase 1/2: Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in NDMM
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma The purpose of this...
79
Dec 9, 2005
NCT00111319: Phase 3 : VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in NDMM
Phase 3 VISTA Study phase III VISTA trial (Velcade As Initial Standard Therapy in Multiple Myeloma: Assessment With Melphalan and...
156
Dec 13, 2002
NCT00048230: Phase 3 - PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With RRMM
Phase 3 - PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma NCT00048230 This...
132